A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Donepezil (Aricept)

Donepezil slows cognitive decline in Alzheimer's disease by preserving acetylcholine levels.

First FDA approval1996-11-25
Generic availableYes · 20 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$158.0M in CY2024 Part D spend12.3M claims · 2.9M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.044/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.044
Across all dosage forms in distribution.
Highest NADAC
$0.044
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Donepezil used for?

Donepezil slows cognitive decline in Alzheimer's disease by preserving acetylcholine levels.

Is there a generic for Donepezil?

Yes. 41 ANDAs filed at FDA, 20 generic manufacturers currently shipping.

How much does my plan pay for Donepezil?

Across 329 Part D plans, Donepezil averages $0.044/unit (NADAC). Lowest available: $0.044/unit. Highest in distribution: $0.044/unit.

Is Donepezil on the FDA shortage list?

No. Donepezil is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cholinesterase Inhibitor4 alternatives in D1
01
Malathion
Brand: Ovide
$3.19Lowest NADAC
1Generic mfrs
$515,631CY24 Part D spend
Compare →
02
Neostigmine Methylsulfate
Brand: Bloxiverz
Lowest NADAC
14Generic mfrs
CY24 Part D spend
Compare →
03
Pyridostigmine
Brand: Mestinon
$0.273Lowest NADAC
11Generic mfrs
$57.5MCY24 Part D spend
Compare →
04
Rivastigmine
Brand: Exelon
$0.150Lowest NADAC
13Generic mfrs
$145.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.